Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
A 47-year-old man who became the first person to be convicted in England and Wales of conspiracy to commit female genital mutilation (FGM) received a four-and-a-half year prison term on Thursday (3).
Emad Kaky, formerly a doctorate student at the University of Nottingham in central England, made arrangements for a young girl to travel from the UK to Iraq, where he "clearly" intended that she undergo FGM, the Crown Prosecution Service (CPS) said.
A jury at Nottingham Crown Court found him guilty of conspiracy to commit FGM and forced marriage following a two-week trial.
On sentencing, judge Nirmal Shant called Kaky's planned actions "barbaric".
"When considering the seriousness of the offence I look not just at the harm that occurred, it didn't in this case but, in fact, the intended harm," she said.
"You made concerted efforts to make sure this happened. This offence calls for a deterrent sentence. What you did, what you had planned, was barbaric."
The CPS, which brings prosecutions in England and Wales, said the 47-year-old's conviction was the "first of its kind" in England and Wales.
A woman was jailed in February for having assisted in the genital mutilation of a three-year-old girl during a trip to Kenya and another woman in 2019 was jailed for 11 years for cutting a three-year-old girl.
They were the only people to be convicted under the FGM Act of 2003 before Kaky's case, and he is the first to be found guilty of conspiracy to commit FGM.
"This has been a landmark prosecution, not just because it is the first conviction of its kind, but for the message it sends to people who may be vulnerable to this horrific form of abuse," said the CPS's Jaswant Narwal.
"Where there is evidence that people have plotted to commit these offences, they face prosecution, whether or not they succeed," she added.
Kaky, from Swansea in southern Wales, booked and paid for the girl's trip while he was living in Nottingham but a witness uncovered his plans and contacted police.
When challenged, Kaky called FGM "normal", his trial was told.
The practice is common in some African, Middle Eastern and Asian countries and involves the partial or total removal of a young girl's clitoris and labia.
The risky procedure is often carried out under unsterile conditions and can lead to severe complications.
According to the WHO, more than 200 million girls and women alive today have been subjected to the practice.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.